CN105838738A - 一种携带ctag1b/ny-eso-1肿瘤抗原基因的自补型重组腺相关病毒载体及构建方法和应用 - Google Patents
一种携带ctag1b/ny-eso-1肿瘤抗原基因的自补型重组腺相关病毒载体及构建方法和应用 Download PDFInfo
- Publication number
- CN105838738A CN105838738A CN201610179322.6A CN201610179322A CN105838738A CN 105838738 A CN105838738 A CN 105838738A CN 201610179322 A CN201610179322 A CN 201610179322A CN 105838738 A CN105838738 A CN 105838738A
- Authority
- CN
- China
- Prior art keywords
- ctag1b
- eso
- gene
- carrier
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 title claims abstract description 120
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 title claims abstract description 75
- 108091058556 CTAG1B Proteins 0.000 title claims abstract description 62
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 47
- 108091007433 antigens Proteins 0.000 title claims abstract description 43
- 238000010276 construction Methods 0.000 title claims abstract description 18
- 241000702421 Dependoparvovirus Species 0.000 title abstract description 18
- 239000000427 antigen Substances 0.000 claims abstract description 21
- 102000036639 antigens Human genes 0.000 claims abstract description 21
- 238000009169 immunotherapy Methods 0.000 claims abstract description 13
- 230000001413 cellular effect Effects 0.000 claims abstract description 9
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 101150090257 CTAG1B gene Proteins 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 239000013612 plasmid Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 19
- 239000013603 viral vector Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000007850 degeneration Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 210000004907 gland Anatomy 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 230000004087 circulation Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004925 denaturation Methods 0.000 claims description 5
- 230000036425 denaturation Effects 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 238000010839 reverse transcription Methods 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 108010042407 Endonucleases Proteins 0.000 claims description 3
- 102000004533 Endonucleases Human genes 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims 5
- 230000007096 poisonous effect Effects 0.000 claims 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 238000000137 annealing Methods 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 4
- 108091008146 restriction endonucleases Proteins 0.000 abstract description 2
- 238000012163 sequencing technique Methods 0.000 abstract description 2
- 238000010367 cloning Methods 0.000 abstract 1
- 238000001976 enzyme digestion Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- 210000004443 dendritic cell Anatomy 0.000 description 26
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 229920002873 Polyethylenimine Polymers 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000012797 qualification Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 3
- 229960004359 iodixanol Drugs 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- -1 CD86 Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610179322.6A CN105838738B (zh) | 2016-03-24 | 2016-03-24 | 一种携带ctag1b/ny-eso-1肿瘤抗原基因的自补型重组腺相关病毒载体及构建方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610179322.6A CN105838738B (zh) | 2016-03-24 | 2016-03-24 | 一种携带ctag1b/ny-eso-1肿瘤抗原基因的自补型重组腺相关病毒载体及构建方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105838738A true CN105838738A (zh) | 2016-08-10 |
CN105838738B CN105838738B (zh) | 2019-06-21 |
Family
ID=56583565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610179322.6A Active CN105838738B (zh) | 2016-03-24 | 2016-03-24 | 一种携带ctag1b/ny-eso-1肿瘤抗原基因的自补型重组腺相关病毒载体及构建方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105838738B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103014064A (zh) * | 2011-09-22 | 2013-04-03 | 北京五加和分子医学研究所有限公司 | Itr同向排列的aav载体构建及其应用 |
CN103060331A (zh) * | 2012-12-05 | 2013-04-24 | 南京医科大学第一附属医院 | 介导膜稳定cd40l基因的衣壳蛋白突变的双链重组腺相关病毒制备方法与应用 |
CN103626877A (zh) * | 2013-11-27 | 2014-03-12 | 苏州工业园区唯可达生物科技有限公司 | 含ny-eso-1的融合蛋白、制备方法及应用 |
-
2016
- 2016-03-24 CN CN201610179322.6A patent/CN105838738B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103014064A (zh) * | 2011-09-22 | 2013-04-03 | 北京五加和分子医学研究所有限公司 | Itr同向排列的aav载体构建及其应用 |
CN103060331A (zh) * | 2012-12-05 | 2013-04-24 | 南京医科大学第一附属医院 | 介导膜稳定cd40l基因的衣壳蛋白突变的双链重组腺相关病毒制备方法与应用 |
CN103626877A (zh) * | 2013-11-27 | 2014-03-12 | 苏州工业园区唯可达生物科技有限公司 | 含ny-eso-1的融合蛋白、制备方法及应用 |
Non-Patent Citations (5)
Title |
---|
AUNG PP ET AL.: "Homo sapiens cancer/testis antigen 1B(CTAG1B),mRNA,Accession NO:NM_001327.2", 《GENBANK》 * |
DM MCCARTY ET AL.: "Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis", 《GENE THERAPY》 * |
周学智等: "NY-ESO-1致敏树突状细胞诱导的细胞毒性T淋巴细胞对视网膜母细胞瘤细胞的特异性杀伤作用", 《中华实验眼科杂志》 * |
张又莉等: "重组腺病毒载体pAd-NY-ESO-1-EGFP的构建及鉴定", 《郧阳医学院学报》 * |
顾娜等: "NY-ESO-1抗原T细胞受体基因慢病毒载体的构建及鉴定", 《北京医学》 * |
Also Published As
Publication number | Publication date |
---|---|
CN105838738B (zh) | 2019-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11123427B2 (en) | Immunoprotective primary mesenchymal stem cells and methods | |
CN106636090B (zh) | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 | |
CN103898051B (zh) | 提高免疫反应性的方法 | |
Hodge et al. | Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer | |
CN112334573B (zh) | 人类dc细胞扩增方法和人类dc细胞资源库 | |
CN109055430A (zh) | 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法 | |
CN109957548A (zh) | 一种基因修饰的树突状细胞疫苗 | |
CN108715856B (zh) | 一种以人复制缺陷腺病毒为载体的马尔堡病毒病疫苗 | |
Batchu et al. | Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector | |
CN111607571B (zh) | 一种特异性激活免疫共刺激通路的复制型溶瘤腺病毒及其制备方法和应用 | |
CN102787097B (zh) | 经修饰的树突状细胞及包含该树突状细胞的疫苗 | |
WO2023123195A1 (zh) | 一种目的基因可调控的工程化免疫细胞及其制备方法和应用 | |
CN105985984A (zh) | 携带pap抗原基因的重组腺相关病毒载体及构建方法与应用 | |
CN106957822A (zh) | 体外扩增基因编辑活化t细胞的培养方法、试剂盒及应用 | |
CN105039342A (zh) | 能抑制MAT2A基因表达的siRNA及其应用 | |
CN105779480A (zh) | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 | |
CN105838738B (zh) | 一种携带ctag1b/ny-eso-1肿瘤抗原基因的自补型重组腺相关病毒载体及构建方法和应用 | |
CN104434973A (zh) | 一种强化细胞因子诱导的杀伤细胞功能的方法 | |
CN105031632B (zh) | 一种树突状细胞疫苗及其制备方法与应用 | |
CN111548998B (zh) | 一种分泌pd-1抗体的长寿浆细胞及其制备方法与应用 | |
CN113355283A (zh) | 基于rna疫苗的抗原反应性t细胞的制备方法及应用 | |
Chang | Lentiviral vector transduction of dendritic cells for novel vaccine strategies | |
CN108743617A (zh) | miR-15a-5p在提高CAR-T细胞抗肿瘤能力中的应用 | |
CN116640229B (zh) | 一种低pH靶向性CAR-T细胞的构建及应用 | |
CN104388466A (zh) | 一种复制缺陷性重组腺病毒rAd-RNAi-SOCS1及其制备方法和其在治疗肿瘤中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A self complementary recombinant adeno-associated virus vector carrying ctag1b / NY-ESO-1 tumor antigen gene and its construction method and Application Effective date of registration: 20210507 Granted publication date: 20190621 Pledgee: Agricultural Bank of China Limited by Share Ltd. Chengdu Wenjiang branch Pledgor: CHENGDU KANGJING BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021980003309 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231013 Granted publication date: 20190621 Pledgee: Agricultural Bank of China Limited by Share Ltd. Chengdu Wenjiang branch Pledgor: CHENGDU KANGJING BIOTECHNOLOGY CO.,LTD. Registration number: Y2021980003309 |